CTI BioPharma has one FDA-approved therapy, Vonjo, to treat a rare form of bone marrow cancer. The company is being bought at a 89% premium from its closing price on Tuesday. CTI will become a wholly ...
(RTTNews) - CTI BioPharma (CTIC) has entered into a definitive agreement under which Swedish Orphan Biovitrum AB or Sobi will acquire CTI for $9.10 per share of common stock in an all-cash deal, ...
SOBI offers 89% premium for CTI BioPharma Deal to be partly funded by share issue SOBI shares slide 16% SOBI said it would make a tender offer for $9.10 per CTI share, a premium of 89% over Tuesday's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback